J1323 Elranatamab-bcmm - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Elranatamab-bcmm

Brand Name:

Elranatamab-bcmm

Strength:

1mg

HCPCS:

J1323

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

BCMA, CD3

Oral (Y/N):

No

FDA Approval Year:

2023

FDA Discontinuation Year:

CMS Effective Date:

April 17, 2024

CMS Discontinuation Date:

Status:

In Use